Bli medlem
Bli medlem

Du är här

2015-03-26

Novo Nordisk A/S : Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US

Bagsværd, Denmark, 26 March 2015 -
Novo Nordisk today announced that the company has decided to submit the
prespecified interim analysis of DEVOTE as part of a Class II Resubmission of
the New Drug Applications (NDAs) of Tresiba®and Ryzodeg®to the US Food and
Drug Administration (FDA). The resubmission is expected to take place within
the next month.

For further information

---------------------------------------------------------------------
| Media: |
| Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com |
| Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com |
| Investors: |
| Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com |
| Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com |
| Daniel Bohsen +45 3079 6376 dabo@novonordisk.com |
| Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com |
---------------------------------------------------------------------
Company Announcement No 23 / 2015

Company Announcement No 23 2015
http://hugin.info/2013/R/1906649/678864.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1906649

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.